Alexion Pharmaceuticals, Inc. (ALXN)
-NasdaqGS 96.20 
0.47(0.49%) 4:00PM EDT|After Hours
:
96.15 0.05 (0.05%) 4:27PM EDT - Nasdaq Real Time Price
| Prev Close: | 96.67 |
|---|
| Open: | 96.38 |
|---|
| Bid: | 94.56 x 200 |
|---|
| Ask: | 97.17 x 200 |
|---|
| 1y Target Est: | 114.25 |
|---|
| Beta: | 0.53 |
|---|
| Next Earnings Date: | 22-Jul-13 |
|---|
| Day's Range: | 95.68 - 97.65 |
|---|
| 52wk Range: | 81.28 - 119.54 |
|---|
| Volume: | 1,171,131 |
|---|
| Avg Vol (3m): | 1,958,660 |
|---|
| Market Cap: | 18.74B |
|---|
| P/E (ttm): | 66.03 |
|---|
| EPS (ttm): | 1.46 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- Raptor's FDA Approval Is New Test For Orphan Drug Pricingat TheStreet(Wed, May 1)
- A Look at Biotechnology’s Hot Name & Its Lack of Valueat Motley Fool(Tue, Apr 30)
- ALEXION PHARMACEUTICALS INC Files SEC form 10-Q, Quarterly ReportEDGAR Online(Tue, Apr 30)
- Raised Guidance And Resolved Manufacturing Issues Support Alexion Sharesat Seeking Alpha(Mon, Apr 29)
- Hepatitis C Space an Opportunity with the Potential for an Upside Surprise, According to Expert Analyst David FerreiroWall Street Transcript(Fri, Apr 26)
- Mark A. Emalfarb, Founder, Chairman, President and CEO of Dyadic International (DYAI), Interviews with The Wall Street TranscriptWall Street Transcript(Fri, Apr 26)
- Wall Street gains on earnings, data, but S&P record a hurdleReuters(Thu, Apr 25)
- Biogen Earnings Strong, But Celgene Just So-SoInvestor's Business Daily(Thu, Apr 25)
- US STOCKS-Wall Street rises on earnings, data, but record a hurdleat Reuters(Thu, Apr 25)
- Alexion Pharmaceuticals Management Discusses Q1 2013 Results - Earnings Call Transcriptat Seeking Alpha(Thu, Apr 25)
- ALXN Makes Bullish Cross Above Critical Moving Averageat TheStreet(Thu, Apr 25)
- Alexion Soars on Q1 Resultsat Motley Fool(Thu, Apr 25)
- Alexion Rises On Unusually High Volume (ALXN)at TheStreet(Thu, Apr 25)
- Why Alexion Shares Poppedat Motley Fool(Thu, Apr 25)
- Earnings Beat at Alexion, Ups ViewZacks(Thu, Apr 25)
Key Statistics
| Forward P/E (1 yr): | 29.42 |
|---|
| P/S (ttm): | 15.33 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | 2.90 |
|---|
| Quarterly EPS Est
(Jun-13)
: | 0.67 |
|---|
| Mean Recommendation*: | 1.8 |
|---|
| PEG Ratio (5 yr expected): | 1.08 |
|---|
Business Summary
Alexion Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of life-transforming therapeutic products.
View More